{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:39:38Z","timestamp":1788302378599,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants-in-aid for scientific research","doi-asserted-by":"crossref","award":["20K16238, 24K20198"],"award-info":[{"award-number":["20K16238, 24K20198"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Grants-in-aid for scientific research","doi-asserted-by":"crossref","award":["18KK0231, 22H03336, 22K19658, 23KK0141"],"award-info":[{"award-number":["18KK0231, 22H03336, 22K19658, 23KK0141"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-05929-6","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:33:10Z","timestamp":1778329990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cross-border molecular epidemiology of Plasmodium falciparum drug susceptibility: insights from the Uganda\u2013Democratic Republic of the Congo border"],"prefix":"10.1186","volume":"25","author":[{"given":"Patrick Mamona","family":"Dilufwasayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Balikagala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moise Agenowun","family":"Uchopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques Amanga","family":"Amaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieudonn\u00e9 Mumba","family":"Ngoyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"5929_CR1","unstructured":"World Health Organisation: World malaria report 2024: Addressing inequity in the global malaria response. In World Health Organisation. 2024."},{"key":"5929_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"5929_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","volume":"18","author":"R Amato","year":"2018","unstructured":"Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018;18:337\u201345.","journal-title":"Lancet Infect Dis"},{"key":"5929_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5929_CR5","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","volume":"24","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024;24:e591\u2013600.","journal-title":"Lancet Infect Dis"},{"key":"5929_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J Infect Dis. 2021;223:985\u201394.","journal-title":"J Infect Dis"},{"key":"5929_CR7","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"5929_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5929_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, van Loon W, Habarugira F, Tacoli C, J\u00e4ger JC, Savelsberg D, et al. Increase in Kelch 13 polymorphisms in Plasmodium falciparum, southern Rwanda. Emerg Infect Dis. 2021;27:294\u20136.","journal-title":"Emerg Infect Dis"},{"key":"5929_CR10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"24","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024;24:1225\u201333.","journal-title":"Lancet Infect Dis"},{"key":"5929_CR11","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A, et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8:1911\u20139.","journal-title":"Nat Microbiol"},{"key":"5929_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438\u201347.","journal-title":"Lancet"},{"key":"5929_CR13","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0140-6736(12)60484-X","volume":"379","author":"AP Phyo","year":"2012","unstructured":"Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960\u20136.","journal-title":"Lancet"},{"key":"5929_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/507115","volume":"194","author":"AB Sidhu","year":"2006","unstructured":"Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006;194:528\u201335.","journal-title":"J Infect Dis"},{"key":"5929_CR15","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1128\/AAC.05102-11","volume":"55","author":"NB Gadalla","year":"2011","unstructured":"Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011;55:5408\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"5929_CR16","doi-asserted-by":"publisher","first-page":"e1119","DOI":"10.1093\/infdis\/jiaf155","volume":"231","author":"C Fan\u00e7ony","year":"2025","unstructured":"Fan\u00e7ony C, Fortes-Gabriel E, Zage F, Alexiou E, Broumou I, Pernaute-Lau L, et al. Artemether-lumefantrine treatment selects Plasmodium falciparum multidrug resistance 1 (pfmdr1) increased copy number among African malaria infections. J Infect Dis. 2025;231:e1119\u201328.","journal-title":"J Infect Dis"},{"key":"5929_CR17","unstructured":"World Malaria Day: United States and the Democratic Republic of the Congo Work Together to Support Healthy Communities [https:\/\/www.usaid.gov\/democratic-republic-congo\/press-release\/world-malaria-day-united-states-and-democratic-republic-congo-work-together-support-healthy-communities#:~:text=Malaria%20is%20the%20leading%20cause,malaria%20and%20foster%20healthy%20communities.]"},{"key":"5929_CR18","unstructured":"Unicef: MICS-Paludisme 2017\u20132018: Rapport des r\u00e9sultats de l'enqu\u00eate,Province de L'Ituri. vol. 2023: Unicef; 2018."},{"key":"5929_CR19","unstructured":"DRC NMCPNot: An Epidemiological Profile of malaria in the Democratic Republic of Congo. 2014."},{"key":"5929_CR20","unstructured":"DRC NMCPNot: DRC national strategic plan for malaria control 2007\u20132011. pp. 83. Kinshasa: Minist\u00e8re de la Sant\u00e9 Publique, R\u00e9publique D\u00e9mocratique du Congo; 2007:83."},{"key":"5929_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s41182-023-00551-7","volume":"51","author":"NK Kayiba","year":"2023","unstructured":"Kayiba NK, Tshibangu-Kabamba E, Rosas-Aguirre A, Kaku N, Nakagama Y, Kaneko A, et al. The landscape of drug resistance in Plasmodium falciparum malaria in the Democratic Republic of Congo: a mapping systematic review. Trop Med Health. 2023;51:64.","journal-title":"Trop Med Health"},{"key":"5929_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","volume":"105","author":"LF Moriarty","year":"2021","unstructured":"Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. Am J Trop Med Hyg. 2021;105:1067\u201375.","journal-title":"Am J Trop Med Hyg"},{"key":"5929_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2022.102541","volume":"88","author":"SS Nundu","year":"2022","unstructured":"Nundu SS, Culleton R, Simpson SV, Arima H, Chitama BA, Muyembe JJ, et al. Identification of polymorphisms in genes associated with drug resistance in Plasmodium falciparum isolates from school-age children in Kinshasa, Democratic Republic of Congo. Parasitol Int. 2022;88:102541.","journal-title":"Parasitol Int"},{"key":"5929_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4269\/ajtmh.23-0740","volume":"110","author":"W van Loon","year":"2024","unstructured":"van Loon W, Bisimwa BC, Byela V, Kirby R, Bugeme PM, Balagizi A, et al. Detection of artemisinin resistance marker Kelch-13 469Y in Plasmodium falciparum, South Kivu, Democratic Republic of the Congo, 2022. Am J Trop Med Hyg. 2024;110:653\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"5929_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.026","volume":"139","author":"G Mesia Kahunu","year":"2024","unstructured":"Mesia Kahunu G, Wellmann Thomsen S, Wellmann Thomsen L, Muhindo Mavoko H, Mitashi Mulopo P, Filtenborg Hocke E, et al. Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo. Int J Infect Dis. 2024;139:41\u20139.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"5929_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/infdis\/jiae475","volume":"231","author":"N Wernsman Young","year":"2024","unstructured":"Wernsman Young N, Gashema P, Giesbrecht D, Munyaneza T, Maisha F, Mwebembezi F, et al. High frequency of artemisinin partial resistance mutations in the Great Lakes region revealed through rapid pooled deep sequencing. J Infect Dis. 2024;231(1):269.","journal-title":"J Infect Dis"},{"key":"5929_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15779-8","volume":"11","author":"R Verity","year":"2020","unstructured":"Verity R, Aydemir O, Brazeau NF, Watson OJ, Hathaway NJ, Mwandagalirwa MK, et al. The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC. Nat Commun. 2020;11:2107.","journal-title":"Nat Commun"},{"key":"5929_CR28","unstructured":"UNOCHA: <Rapport de la situation humanitaire pour la Province de l'Ituri - 2 juin 2023 (1).pdf>. UNOCHA 2023."},{"key":"5929_CR29","unstructured":"ARU [https:\/\/caid.cd\/?p=2052]"},{"key":"5929_CR30","volume-title":"Biostatististics: a foundation for analysis in the health sciences","author":"WW Daniel","year":"2013","unstructured":"Daniel WW, Cross CL. Biostatististics: a foundation for analysis in the health sciences. 10th ed. Hoboken: Wiley; 2013.","edition":"10"},{"key":"5929_CR31","volume":"2016","author":"DM Mvumbi","year":"2016","unstructured":"Mvumbi DM, Bobanga TL, Melin P, De Mol P, Kayembe JM, Situakibanza HN, et al. High Prevalence of Plasmodium falciparum Infection in Asymptomatic Individuals from the Democratic Republic of the Congo. Malar Res Treat. 2016;2016:5405802.","journal-title":"Malar Res Treat"},{"key":"5929_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12936-017-2127-y","volume":"16","author":"VA Alegana","year":"2017","unstructured":"Alegana VA, Wright J, Bosco C, Okiro EA, Atkinson PM, Snow RW, et al. Malaria prevalence metrics in low- and middle-income countries: an assessment of precision in nationally-representative surveys. Malar J. 2017;16:475.","journal-title":"Malar J"},{"key":"5929_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad MD, Asua V, Garg S, Giesbrecht D, Niar\u00e9 K, Smith S, et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med. 2023;389:722\u201332.","journal-title":"N Engl J Med"},{"key":"5929_CR34","unstructured":"Bioline\u2122 Malaria Ag P.f [https:\/\/www.globalpointofcare.abbott\/ww\/en\/product-details\/bioline-malaria-ag-pf-hrp-2.html]"},{"key":"5929_CR35","unstructured":"WHO TEAM GMPG: Basic malaria microscopy \u2013 Part II: Tutor's guide. Second edition. In WHO2010."},{"key":"5929_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4269\/ajtmh.1999.60.183","volume":"60","author":"JM Rubio","year":"1999","unstructured":"Rubio JM, Benito A, Roche J, Berzosa PJ, Garc\u00eda ML, Mic\u00f3 M, et al. Semi-nested, multiplex polymerase chain reaction for detection of human malaria parasites and evidence of Plasmodium vivax infection in Equatorial Guinea. Am J Trop Med Hyg. 1999;60:183\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5929_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03249-x","volume":"19","author":"MR Ansbro","year":"2020","unstructured":"Ansbro MR, Jacob CG, Amato R, Kekre M, Amaratunga C, Sreng S, et al. Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2\/3 copy number variation in Plasmodium falciparum. Malar J. 2020;19:181.","journal-title":"Malar J"},{"key":"5929_CR38","unstructured":"Copy number estimation of the Plasmodium falciparum pfmdr1 gene [https:\/\/www.iddo.org\/procedure\/copy-number-estimation-plasmodium-falciparum-pfmdr1-gene]"},{"key":"5929_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57726-5","volume":"16","author":"L Pernaute-Lau","year":"2025","unstructured":"Pernaute-Lau L, Recker M, T\u00e9k\u00e9t\u00e9 M, de Sousa TN, Traore A, Fofana B, et al. Decreased dihydroartemisinin-piperaquine protection against recurrent malaria associated with Plasmodium falciparum plasmepsin 3 copy number variation in Africa. Nat Commun. 2025;16:2680.","journal-title":"Nat Commun"},{"key":"5929_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0166-6851(00)00201-2","volume":"108","author":"MT Duraisingh","year":"2000","unstructured":"Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000;108:13\u201323.","journal-title":"Mol Biochem Parasitol"},{"key":"5929_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1475-2875-11-92","volume":"11","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Tanabe K, Tsukahara T, Dzodzomenyo M, Dysoley L, Khamlome B, et al. Large-scale survey for novel genotypes of Plasmodium falciparum chloroquine-resistance gene pfcrt. Malar J. 2012;11:92.","journal-title":"Malar J"},{"key":"5929_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"5929_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12936-020-03157-0","volume":"19","author":"B Balikagala","year":"2020","unstructured":"Balikagala B, Sakurai-Yatsushiro M, Tachibana SI, Ikeda M, Yamauchi M, Katuro OT, et al. Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda. Malar J. 2020;19:76.","journal-title":"Malar J"},{"key":"5929_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179142","volume":"12","author":"DM Mvumbi","year":"2017","unstructured":"Mvumbi DM, Bobanga TL, Kayembe JN, Mvumbi GL, Situakibanza HN, Benoit-Vical F, et al. Molecular surveillance of Plasmodium falciparum resistance to artemisinin-based combination therapies in the Democratic Republic of Congo. PLoS ONE. 2017;12:e0179142.","journal-title":"PLoS ONE"},{"key":"5929_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01525-23","volume":"68","author":"PR Dimbu","year":"2024","unstructured":"Dimbu PR, Labuda S, Ferreira CM, Caquece F, Andr\u00e9 K, Pembele G, et al. Therapeutic response to four artemisinin-based combination therapies in Angola, 2021. Antimicrob Agents Chemother. 2024;68:e0152523.","journal-title":"Antimicrob Agents Chemother"},{"key":"5929_CR46","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1086\/503423","volume":"42","author":"RN Price","year":"2006","unstructured":"Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006;42:1570\u20137.","journal-title":"Clin Infect Dis"},{"key":"5929_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697\u2013704.","journal-title":"Antimicrob Agents Chemother"},{"key":"5929_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-025-05423-5","volume":"24","author":"KJ Marwa","year":"2025","unstructured":"Marwa KJ, Kilonzi M, Mnkugwe RH, Baraka V, Kapesa A, Mwaiswelo R, et al. Prevalence of Plasmodium falciparum plasmepsin2\/3 gene duplication in Africa and Asia: a systematic review and meta-analysis. Malar J. 2025;24:266.","journal-title":"Malar J"},{"key":"5929_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00413-22","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Liang X, Li J, Chen J, Huang H, Zheng Y, et al. Molecular surveillance of Artemisinin-based combination therapies resistance in Plasmodium falciparum parasites from Bioko Island, Equatorial Guinea. Microbiol Spectr. 2022;10:e0041322.","journal-title":"Microbiol Spectr"},{"key":"5929_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01516-17","author":"SA Rasmussen","year":"2017","unstructured":"Rasmussen SA, Ceja FG, Conrad MD, Tumwebaze PK, Byaruhanga O, Katairo T, et al. Changing antimalarial drug sensitivities in Uganda. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01516-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"5929_CR51","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/S2666-5247(21)00085-9","volume":"2","author":"PK Tumwebaze","year":"2021","unstructured":"Tumwebaze PK, Katairo T, Okitwi M, Byaruhanga O, Orena S, Asua V, et al. Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study. Lancet Microbe. 2021;2:e441\u20139.","journal-title":"Lancet Microbe"},{"key":"5929_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02652-2","volume":"20","author":"DM Wakoli","year":"2022","unstructured":"Wakoli DM, Ondigo BN, Ochora DO, Amwoma JG, Okore W, Mwakio EW, et al. Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs. BMC Med. 2022;20:448.","journal-title":"BMC Med"},{"key":"5929_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J"},{"key":"5929_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240174","volume":"15","author":"H Gupta","year":"2020","unstructured":"Gupta H, Galatas B, Chidimatembue A, Huijben S, Cister\u00f3 P, Matambisso G, et al. Effect of mass dihydroartemisinin-piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance. PLoS ONE. 2020;15:e0240174.","journal-title":"PLoS ONE"},{"key":"5929_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-05240-2","volume":"24","author":"D Duarte","year":"2025","unstructured":"Duarte D, Manuel F, Dias A, Sacato E, Taleingue E, Daniel E, et al. Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern Angola. Malar J. 2025;24:5.","journal-title":"Malar J"},{"key":"5929_CR56","unstructured":"DRC NMCPNot: DRC national strategic plan for malaria control 2020\u20132023. pp. 1172020:117."},{"key":"5929_CR57","doi-asserted-by":"crossref","unstructured":"Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, Bakari C, Madebe RA, Seth MD, Mandara CI, et al: Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medRxiv 2023.","DOI":"10.1101\/2023.11.07.23298207"},{"key":"5929_CR58","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"5929_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07112-z","volume":"22","author":"DM Yobi","year":"2022","unstructured":"Yobi DM, Kayiba NK, Mvumbi DM, Boreux R, Kabututu PZ, Akilimali PZ, et al. Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019. BMC Infect Dis. 2022;22:145.","journal-title":"BMC Infect Dis"},{"key":"5929_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03192-x","volume":"19","author":"DM Yobi","year":"2020","unstructured":"Yobi DM, Kayiba NK, Mvumbi DM, Boreux R, Kabututu PZ, Situakibanza HNT, et al. Molecular surveillance of anti-malarial drug resistance in Democratic Republic of Congo: high variability of chloroquinoresistance and lack of amodiaquinoresistance. Malar J. 2020;19:121.","journal-title":"Malar J"},{"key":"5929_CR61","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/infdis\/jiae288","volume":"230","author":"S Tukwasibwe","year":"2024","unstructured":"Tukwasibwe S, Garg S, Katairo T, Asua V, Kagurusi BA, Mboowa G, et al. Varied prevalence of antimalarial drug resistance markers in different populations of newly arrived refugees in Uganda. J Infect Dis. 2024;230:497\u2013504.","journal-title":"J Infect Dis"},{"key":"5929_CR62","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01576-23","volume":"68","author":"R Ogwang","year":"2024","unstructured":"Ogwang R, Osoti V, Wamae K, Ndwiga L, Muteru K, Ningwa A, et al. A retrospective analysis of P. falciparum drug resistance markers detects an early (2016\/17) high prevalence of the k13 C469Y mutation in asymptomatic infections in Northern Uganda. Antimicrob Agents Chemother. 2024;68:e0157623.","journal-title":"Antimicrob Agents Chemother"},{"key":"5929_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62810-x","volume":"16","author":"M Okitwi","year":"2025","unstructured":"Okitwi M, Orena S, Tumwebaze PK, Katairo T, Taremwa Y, Byaruhanga O, et al. Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019-2024. Nat Commun. 2025;16:7353.","journal-title":"Nat Commun"},{"key":"5929_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01930-24","volume":"69","author":"NI Proellochs","year":"2025","unstructured":"Proellochs NI, Andolina C, Ramjith J, Stoter R, van Gemert GJ, Graumans W, et al. Gametocyte production and transmission fitness of African and Asian Plasmodium falciparum isolates with differential susceptibility to artemisinins. Antimicrob Agents Chemother. 2025;69:e0193024.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05929-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05929-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05929-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:03:12Z","timestamp":1782100992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05929-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5929"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05929-6","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained from the National Health Ethics Committee (CNES) of the DRC (Approval number: 416\/CNES\/BN\/PMMF\/2022) and Juntendo Research and Ethics Committee (Approval number: E23-0023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Prior to participation, all study subjects consented to the publication of study results in medical literature in an anonymized manner.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}